Talisman Metals (TLM) investor relations material

Executive summary

• 2025 marked a transformational year, shifting from biopharmaceuticals to copper exploration in Morocco, culminating in the acquisition of Tadeen International Limited and a fundamental change of business focus.

• The company completed the sale of its biopharmaceutical subsidiary, exited R&D, and delisted from Euronext Growth, focusing on AIM readmission and capital raising.

• Shareholders approved the acquisition, fundraising, share consolidation, and name change to Talisman Metals Plc in January 2026.

Financial highlights

• Group reported a total comprehensive profit of €1,687k / US$3,427k for 2025, compared to a loss of €1,246k / US$1,525k in 2024.

• Net loss for the company was €116k / US$136k in 2025, a significant improvement from €4,568k / US$5,350k loss in 2024.

• Cash and cash equivalents at year-end were €2,005k / US$2,359k (2024: €2,506k / US$2,610k).

• Accumulated losses increased to €30,752k / US$34,099k (2024: €17,891k / US$19,185k).

• No dividend was declared for 2025.

Outlook and guidance

• 2026 will focus on fieldwork at Moroccan copper projects, aiming to establish resources at Fougnar and Tirzzit.

• Management expects to maintain a positive cash position for at least 12 months, with sufficient funding for planned activities.

• Ongoing efforts to raise market awareness and attract new investors.